N-terminal probrain natriuretic peptide in patients with acute coronary syndrome .
To observe the changes and evaluate the significance of serum N-terminal probrain natriuretic peptide (NT-proBNP) levels in patients with acute coronary syndrome and to discuss its clinical significance and relationship with the severity of disease. Serum NT-proBNP levels were determined rapidly by using the triage BNP test for 98 consecutive patients with coronary heart disease (CAD) admitted to the hospital from March 2013 to December 2013; the correlation between the concentration of NT-proBNP and the degree of severity of the disease was analyzed. The levels of NT-proBNP in the acute myocardial infarction (AMI) group were higher compared with unstable angina pectoris (UAP), stable angina pectoris (SAP), and control groups, and the levels of NT-proBNP in UAP were higher compared to the SAP and control groups. Levels of NT-proBNP in the extensive anterior wall infarction group were higher compared to that of the inferior or anteroseptal wall infarction groups: p < 0.05; the levels of NT-proBNP in the inferior wall and posterior wall infarction group were higher compared with the inferior wall infarction group and anteroseptal wall infarction group: p < 0.05; the levels of NT-proBNP in the multi-vessel group were higher than those in the single-vessel group: p < 0.05. The BNP level was positively correlated with age, heart rate, creatinine kinase-myocardial band (CK-MB), cardiac troponin T (cTnT), and blood urea nitrogen (BUN), whereas it was negatively correlated with left ventricular ejection fraction (LVEF). NT-proBNP is related to the lowering of left ventricular ejection fraction and the severity of myocardial ischemia. .